Zymeworks (ZYME) Net Income towards Common Stockholders Growth (3y) (2024 - 2026)
Zymeworks (ZYME) Net Income towards Common Stockholders Growth (3y) (2024 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
-10.84% |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
26.38% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
-46.86% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
34.98% |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
Zymeworks |
1.71 Bn |
1.35 Bn |
- |
-21.95% |
| Date | Value |
|---|
| Mar 31, 2026 |
-21.95% |
| Dec 31, 2025 |
-28.73% |
| Sep 30, 2025 |
25.73% |
| Jun 30, 2025 |
26.74% |
| Mar 31, 2025 |
32.20% |
| Dec 31, 2024 |
15.64% |
| Sep 30, 2024 |
21.02% |
